<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003359</url>
  </required_header>
  <id_info>
    <org_study_id>98-004</org_study_id>
    <secondary_id>CDR0000066341</secondary_id>
    <secondary_id>TULA-T9801</secondary_id>
    <secondary_id>NCI-G98-1443</secondary_id>
    <nct_id>NCT00003359</nct_id>
  </id_info>
  <brief_title>T138067 Sodium in Treating Patients With Advanced Refractory Cancer</brief_title>
  <official_title>Phase I Dose Escalation Study to Evaluate the Safety of T138067-Sodium in Patients With Advanced Refractory Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating patients with&#xD;
      advanced refractory cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of T138067 sodium that can be given to&#xD;
      patients with advanced refractory cancer on a 28-day schedule and establish a dose for&#xD;
      further study. II. Evaluate the safety and dose limiting toxicity of T138067 sodium in these&#xD;
      patients. III. Determine the pharmacokinetic parameters after a single intravenous dose of&#xD;
      this agent in these patients. IV. Obtain safety data and preliminary efficacy information&#xD;
      after repetition of single doses of T138067 sodium in these patients.&#xD;
&#xD;
      OUTLINE: This is an open label, dose escalation study. Patients receive T138067 sodium by IV&#xD;
      over 3 hours. Patients may be retreated every 4 weeks for up to 6 courses (6 months total) in&#xD;
      the absence of disease progression or dose limiting toxicity (DLT). At least 3 patients are&#xD;
      treated at each dose level in the absence of DLT. The maximum tolerated dose is defined as&#xD;
      the dose level where 2 of 3-6 patients experience DLT.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-24 patients will be accrued into this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">January 2001</completion_date>
  <primary_completion_date type="Actual">January 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>batabulin sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed advanced refractory cancer Must meet one&#xD;
        of the following criteria: - Failed at least 1 regimen of radiotherapy, chemotherapy, or&#xD;
        immunotherapy and not a candidate for a regimen of higher efficacy - Refractory to existing&#xD;
        standard therapy and not candidate for a regimen of higher efficacy - Advanced malignancy&#xD;
        for which there is no standard chemotherapy available No known brain metastases or&#xD;
        leptomeningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: Greater than 3 months Hematopoietic: Absolute neutrophil count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Prothrombin time at least 30% of control&#xD;
        Partial thromboplastin time at least 30% of control Hepatic: Bilirubin less than 2 mg/dL&#xD;
        ALT and AST no greater than 2 times normal Alkaline phosphatase no greater than 2 times&#xD;
        normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min&#xD;
        Cardiovascular: No New York Heart Association class III or IV heart disease No myocardial&#xD;
        infarction in the past 6 months Other: No immunodeficiency syndrome (acquired or&#xD;
        congenital) No uncontrolled infection No significant comorbidity that may compromise&#xD;
        participation in this study Not pregnant Effective contraception required of all fertile&#xD;
        patients during and until 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks&#xD;
        since prior immunotherapy No concurrent immunotherapy or biologic response modifier therapy&#xD;
        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No&#xD;
        concurrent chemotherapy Endocrine therapy: No concurrent corticosteroids Radiotherapy: See&#xD;
        Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent&#xD;
        radiotherapy Surgery: At least 3 weeks since any prior major surgery Other: No organ&#xD;
        allograft At least 30 days since any prior investigational agents No concurrent&#xD;
        nonsteroidal antiinflammatory agents or aspirin No concurrent alternative therapies (i.e.,&#xD;
        herbal medicines, high doses of vitamins) No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Spriggs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jahan TM, Sandler A, Burris H, et al.: A phase II study of T138067-sodium in prior taxane-treated patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1282, 2002.</citation>
  </reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2004</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

